Aziz Kabeer 4

What Happened

• Aziz Kabeer, a member of AN2 Therapeutics' board of directors, was issued 3,775 shares on 2026-04-10 as a grant/award (transaction code A). The filing reports an acquisition price of $0.00 (shares issued in lieu of cash compensation); the reported transaction value is $0.
• All 3,775 shares vest immediately per the filing (see footnote F1). This is an issuance of compensation rather than an open‑market buy or sale.

Key Details

• Transaction date: 2026-04-10; Price reported: $0.00 per share (award issued in lieu of cash).
• Shares acquired: 3,775; total reported transaction value: $0.
• Shares owned after transaction: not specified in this Form 4 filing.
• Relevant footnotes: F1 — shares issued in lieu of cash under the non‑employee director compensation policy and all shares vest immediately. F2/F3 — disclosures about certain shares being held by Adjuvant funds and potential shared voting/dispositive power; those notes disclaim beneficial ownership except to the extent of pecuniary interest.
• Filing timeliness: filed on 2026-04-10 for a transaction on the same date (no late filing indicated).

Context

• Awards issued in lieu of cash are a form of routine director compensation and reflect receipt of equity rather than a market purchase; immediate vesting means the director has full ownership of these shares upon issuance.
• Such compensation grants do not necessarily indicate the insider’s market view and should be considered alongside other insider transactions and company developments.